Coaxum Wole C
Known title: DirectorCIK: 0001826516
Coaxum Wole C's purchase track record
Coaxum Wole C has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/8/2023 | SIGI | $35K | -1.9% | +0.6% | +6.8% |
| 3/6/2023 | SIGI | $100K | -3.9% | -2.6% | +11.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SIGI | ▲ Buy | Grant | 1,606 | $0 | 5/2/2025 | View on chart |
| SIGI | ▼ Sell | Open Market | 1,903 | $174K | 11/4/2024 | View on chart |
| SIGI | ▲ Buy | Grant | 1,141 | $0 | 5/3/2024 | View on chart |
| SIGI | ▲ Buy | Open Market | 351 | $35K | 6/8/2023 | View on chart |
| SIGI | ▲ Buy | Grant | 1,065 | $0 | 5/5/2023 | View on chart |
| SIGI | ▲ Buy | Open Market | 1,000 | $100K | 3/6/2023 | View on chart |
| SIGI | ▲ Buy | Grant | 1,172 | $0 | 5/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Selective Insurance Sets Date for Q3 2026 Earnings Release
Selective Insurance Group has announced it will report third-quarter 2026 results next week. Wall Street analysts generally expect earnings growth for the company during this period. The upcoming release offers a key update on the insurer's performance, with current average price targets from seven analysts sitting at $101.86.
Selective Insurance Sets Date for Q3 2026 Earnings Release. Selective Insurance Group has announced it will report third-quarter 2026 results next week. Wall Street analysts generally expect earnings growth for the company during this period. The upcoming release offers a key update on the insurer's performance, with current average price targets from seven analysts sitting at $101.86.